WinGuan Patent and Trademark Attorneys is a boutique patent law firm established in 2014 by a group of experienced patent attorneys. The firm is based in Canton, China and consulting for global clients on patent prosecution and litigation activities. Having practicing in different industries, the firm's attorneys have a particular focus on pharmaceutical, biotechnology, and chemistry areas.
Not unusual, patent applications covering the later-discovered candidates face inventive-step challenge by those previous disclosures.
Recently, two Chinese patents directing to the type-2 diabetes drug, Alogliptin, produced and sold under trade name “NESINA” by Takeda, Japan were invalidated by the Reexamination and Invalidation Department (“RID”) of the China National IP Administration (“CNIPA”). This sparks a widespread concern regarding the validity check of priority claiming before the CNIPA.